Drug Trial Radar · NCT01482104
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Actual
Start
Jun 2012
Primary completion
Oct 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Norwegian University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Akershus Dermatological Centre; Helse Stavanger HF; Oslo University Hospital; Førde Central Hospital; Haukeland University Hospital; Hudlegekontoret Lillehammer; Hudlegene på Holtet DA
- First posted
- Nov 30, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Basal cell carcinoma (BCC) is the most common malignant skin lesion in white adults. It is a slow-growing tumour which despite low metastatic potential may cause significant local tissue destruction and patient morbidity. Methyl aminolevulinate cream plus photodynamic therapy (MAL-PDT) for BCC is currently approved for a procedure using 2 treatment sessions 1 week apart. This procedure is considered quite time- and resource-consuming. Introducing a single treatment session, with a new PDT session for treatment failures after 3 months, might represent an attractive simplification. This randomised controlled single-blinded multi-centre study primarily aims to compare BCC lesion response rate of two treatment schedules: (a) 1 single treatment of Metvix-PDT with re-treatment of non-complete responders by 3 months, and (b) the usual schedule of 2 standard Metvix(R) PDT treatments 1 week apart. Secondary objectives are to investigate the treatment response in relation to clinical and histological tumour characteristics such as tumour thickness, subtype and immunohistochemical markers.
Conditions
- Skin Neoplasms
- Carcinoma, Basal Cell
Interventions
MAL-PDT re-treatmentDrug
a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
usual MAL-PDTDrug
schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- lesions response rateTime frame: 3 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Dept Dermatology, Haukeland University Hospital
Bergen, Norway
Central Hospital Førde
Førde, Norway
Hudlegekontoret Lillehammer AS
Lillehammer, Norway
Akerskus Dermatological Centre
Lørenskog, Norway
Dept Dermatology, Oslo University Hospital
Oslo, Norway
Dept Surgery, Oslo University Hospital
Oslo, Norway
Hudlegen på Holtet
Oslo, Norway
Dept Dermato-Venereology, Stavanger University Hospital
Stavanger, Norway
Department of Cancer Research and Molecular Medicine, NTNU
Trondheim, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.